Donor T-Cells take on stubborn CMV in transplant patients

NCT ID NCT02210078

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether immune cells from donors who have been exposed to CMV can treat persistent CMV infections in patients who have had a stem cell transplant. The study includes 49 participants with CMV that hasn't improved with standard antiviral drugs. The cells are given intravenously, and the goal is to clear the infection without needing additional doses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
donor cytomegalovirus-specific cytotoxic T-lymphocytes (immune cells)
What this could lead to
If it works, this could offer a way to control CMV infections in patients with weakened immune systems after stem cell transplants.
What could go wrong
This is a small, early-phase trial with only 49 participants. The treatment may not work for everyone, and there are risks like graft-versus-host disease or the infection not clearing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRAL INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.